Irinotécan And NotM. Vuilhorgne
List of bibliographic references
Number of relevant bibliographic references: 6.Ident. | Authors (with country if any) | Title |
---|---|---|
005D48 | H. M. Dodds [Australie] ; S. J. Clarke [Australie] ; M. Findlay [Nouvelle-Zélande] ; J. F. Bishop [Australie] ; J. Robert [France] ; L. P. Rivory [Australie] | Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance |
006239 | H. M. Dodds [Australie] ; J. Robert [France] ; L. P. Rivory [Australie] | The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry |
006343 | M.-C. Haaz [France] ; L. Rivory [Australie] ; C. Riche [France] ; L. Vernillet [France] ; J. Robert [France] | Metabolism of irinotecan (CPT-11) by human hepatic microsomes : Participation of cytochrome P-450 3A and drug interactions |
006488 | M.-C. Haaz [France] ; C. Riche [France] ; L. P. Rivory [Australie] ; J. Robert [France] | Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1 -piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes |
006658 | L. P. Rivory [Australie] ; M.-C. Haaz [France] ; P. Canal [France] ; F. Lokiec [France] ; J.-P. Armand [France] ; J. Robert [France] | Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials |
006965 | L. P. Rivory [Australie] ; M. R. Bowles [Australie] ; J. Robert [France] ; S. M. Pond [Australie] | Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase |
This area was generated with Dilib version V0.6.33. |